Trials / Completed
CompletedNCT02107391
Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer
Randomized, Open-label, Parallel-group, Multi-centre Phase II Clinical Trial of Active Cellular Immunotherapy With Preparation DCVAC/PCa in Combination With Hormone Therapy in Patients With Metastatic Prostate Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- SOTIO a.s. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether DCVAC/PCa added onto hormone therapy can improve PSA progression times for patients with Metastatic Prostate Cancer.
Detailed description
Use of vaccine to improve Prostate Specific Antigen (PSA) levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Dendritic Cells DCVAC/PCa | Combination therapy with DCVAC/PCA add on to and Standard of Care Hormone Therapy |
| DRUG | Leuprolide acetate | Standard of Care Hormone Therapy as an Active Comparator |
| DRUG | Goserelin Acetate | Standard of Care Hormone Therapy as an Active Comparator |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2015-12-01
- Completion
- 2016-06-01
- First posted
- 2014-04-08
- Last updated
- 2017-05-24
Locations
9 sites across 1 country: Czechia
Source: ClinicalTrials.gov record NCT02107391. Inclusion in this directory is not an endorsement.